Evidence map›Paper›PMID 40108661›Full record

ArticleJournal of translational medicine2025

Asymptomatic vivax malaria is associated with an IFN-γ-program on adaptive immunity.

Gregório Guilherme Almeida, Camila Medeiros Costa, Pedro Augusto Carvalho Costa, Gabriela Ribeiro Gomes, Maria Marta Figueiredo, Katherine Jéssica Torres, Alex Fiorini de Carvalho, Bruno Vinícius Santos Valiate, Julia Ramos Sampaio, Brener Cunha Carvalho and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Gregório Guilherme AlmeidaLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou/Fiocruz Minas, Minas Gerais, Belo Horizonte, Brasil.
Camila Medeiros CostaLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou/Fiocruz Minas, Minas Gerais, Belo Horizonte, Brasil.
Pedro Augusto Carvalho CostaLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou/Fiocruz Minas, Minas Gerais, Belo Horizonte, Brasil.
Gabriela Ribeiro GomesLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou/Fiocruz Minas, Minas Gerais, Belo Horizonte, Brasil.
Maria Marta FigueiredoLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou/Fiocruz Minas, Minas Gerais, Belo Horizonte, Brasil.
Katherine Jéssica TorresLaboratorio de Malaria, Laboratorios de Investigación y Desarrollo, Facultad de Ciencias y Filosofía, Universidad Peruana Cayetano Heredia, Lima, Peru.
Alex Fiorini de CarvalhoCT vacinas, Universidade Federal de Minas Gerais e Instituto René Rachou, Fundação Oswaldo Cruz, Minas Gerais, Belo Horizonte, Brasil.
Bruno Vinícius Santos ValiateLaboratório de Imunopatologia, Instituto René Rachou/Fiocruz Minas, Belo Horizonte, MG, Brasil.
Julia Ramos SampaioLaboratório de Imunopatologia, Instituto René Rachou/Fiocruz Minas, Belo Horizonte, MG, Brasil.
Brener Cunha CarvalhoLaboratório de Imunopatologia, Instituto René Rachou/Fiocruz Minas, Belo Horizonte, MG, Brasil.
Dhelio Batista PereiraAmbulatório de Malária, Centro de Pesquisa em Medicina Tropical, Porto Velho, Rondônia, Brazil.
Alexia MartinesAmbulatório de Malária, Centro de Pesquisa em Medicina Tropical, Porto Velho, Rondônia, Brazil.
Mauro Shugiro TadaAmbulatório de Malária, Centro de Pesquisa em Medicina Tropical, Porto Velho, Rondônia, Brazil.
Irene Silva SoaresDepartamento de Análises Clínicas e Toxicológicas, Faculdade de Ciências Farmacêuticas, Universidade de São Paulo, São Paulo, São Paulo, Brasil.
Jamie PonmattamDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Marcia Caldas de CastroDepartment of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA, United States of America.
Douglas Taylor GolenbockDivision of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, United States of America.
Ricardo Tostes GazzinelliLaboratório de Imunopatologia, Instituto René Rachou/Fiocruz Minas, Belo Horizonte, MG, Brasil.
Lis Ribeiro do Valle AntonelliLaboratório de Biologia e Imunologia de Doenças Infecciosas e Parasitárias, Instituto René Rachou/Fiocruz Minas, Minas Gerais, Belo Horizonte, Brasil. lis.antonelli@fiocruz.br.

Funding

Sugar-feeding behavior of the malaria vector Nyssorhynchus darlingi and development of effective attractive toxic sugar baits (ATSB) to increase intervention success in PeruU19AI089681 · NIAID · YALE UNIVERSITY · PI FERREIRA, MARCELO URBANO · 2010 to 2023
$20.1M
Innate Immune Activation in MalariaR01AI079293 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI FITZGERALD, KATHERINE A., GOLENBOCK, DOUGLAS T · 2009 to 2024
$10.9M
CNPq/MS-SCTIE-Decit/ Fundação Bill & Melinda Gates 442570/2019-8Conselho Nacional de Desenvolvimento Científico e Tecnológico 403409/2021-7Conselho Nacional de Desenvolvimento Científico e Tecnológico 443240/2023-0Coordenação de Aperfeiçoamento de Pessoal de Ensino Superior 465293/2014-0Fundação de Amparo a Pesquisa de São Paulo 2016/23618-8National Institute of Allergy and Infectious Diseases R01AI079293, U19 AI089681NIAID NIH HHS R01 AI079293NIAID NIH HHS U19 AI089681Rede Mineira de Biomoléculas from Fundação de Amparo à Pesquisa de Minas Gerais Fapemig, RED-00012-14
6 · The paper itself

Abstract

The adaptive immunity against Plasmodium vivax is thought to be essential to limit parasite growth during asymptomatic malaria, preventing the occurrence of symptoms. However, the mechanisms governing clinical immunity during asymptomatic infections are not understood. Here, we investigated the adaptive cellular compartment in asymptomatic P. vivax-infected individuals (ASY) compared to symptomatic patients (SY) and healthy donors (CTL). Our integrative analysis revealed a T

Indexed as

Adaptive ImmunityAsymptomatic InfectionsInterferon-gammaMalaria, VivaxAdultCD4-Positive T-LymphocytesFemaleHumansMaleParasitemiaPlasmodium vivaxTh1 CellsInterferon-gammaAsymptomatic malariaB cellsCD4 T cellsMalariaPlasmodium vivax

Identifiers

PMID40108661
PMCPMC11921515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.